浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Effects of Taohong siwu decoction modified granules on podocyte epithelial-mesenchymal-transition and renal fibrosis in rats with diabetic kidney disease
- ZHONGGUO YAOFANG Vol. 35, Issue 11, Pages: 1327-1333(2024)
- 作者机构：
1.河北医科大学第三医院肾内科，石家庄 050051
2.河北省糖尿病肾脏疾病重点实验室，石家庄 050051
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2024.11.08
CLC： R965Published：15 June 2024，
Received：16 December 2023，
Revised：23 April 2024，
扫 描 看 全 文
白璐,沈士朋,吴苏等.桃红四物汤加味颗粒对糖尿病肾病模型大鼠足细胞上皮-间充质转化及肾脏纤维化的影响 Δ[J].中国药房,2024,35(11):1327-1333.
BAI Lu,SHEN Shipeng,WU Su,et al.Effects of Taohong siwu decoction modified granules on podocyte epithelial-mesenchymal-transition and renal fibrosis in rats with diabetic kidney disease[J].ZHONGGUO YAOFANG,2024,35(11):1327-1333.
白璐,沈士朋,吴苏等.桃红四物汤加味颗粒对糖尿病肾病模型大鼠足细胞上皮-间充质转化及肾脏纤维化的影响 Δ[J].中国药房,2024,35(11):1327-1333. DOI： 10.6039/j.issn.1001-0408.2024.11.08.
BAI Lu,SHEN Shipeng,WU Su,et al.Effects of Taohong siwu decoction modified granules on podocyte epithelial-mesenchymal-transition and renal fibrosis in rats with diabetic kidney disease[J].ZHONGGUO YAOFANG,2024,35(11):1327-1333. DOI： 10.6039/j.issn.1001-0408.2024.11.08.
摘要
目的
2
探讨桃红四物汤加味颗粒对糖尿病肾病（DKD）模型大鼠足细胞上皮-间充质转化（EMT）及肾脏纤维化的影响。
方法
2
随机选取8只大鼠为正常组（予普通饲料），其余大鼠采用高糖高脂饲料联合腹腔注射链脲佐菌素（35 mg/kg）建立DKD模型。将模型大鼠分为模型组、厄贝沙坦组[阳性对照，13.5 mg/（kg·d）
]
、桃红四物汤加味组[6.48 g/（kg·d）
]
，每组最终纳入8只。各组大鼠灌胃相应药物，每日1次，连续干预16周。干预第4、8、12、16周末检测各组大鼠24 h尿蛋白（24 h UTP），末次给药后检测各组大鼠体重、饮水量、饮食量、尿量、空腹血糖、血肌酐（Scr）、尿素氮（BUN）和肾组织中P-钙黏素（P-cadherin）、足细胞裂孔膜蛋白（nephrin）、
α
-平滑肌肌动蛋白（
α
-SMA）、肾母细胞瘤蛋白1（WT1）、转化生长因子β
1
（TGF-β
1
）、Ⅳ型胶原蛋白（Col-Ⅳ）mRNA及蛋白的表达情况，观察肾组织病理形态学变化并测量肾小球基底膜厚度。
结果
2
与模型组比较，桃红四
物汤加味组大鼠从第8周末开始24 h UTP显著降低，体重显著增长，饮水量、尿量均显著减少，Scr、BUN水平和
α
-SMA mRNA以及TGF-β
1
、Col-Ⅳ mRNA及蛋白表达水平均显著降低，P-cadherin、nephrin、WT1 mRNA表达水平均显著升高（
P
＜0.05）；
α
-SMA蛋白沉积减少，P-cadherin、nephrin、WT1蛋白沉积均增多；大鼠肾组织病理损伤及纤维化程度减轻，肾小球基底膜厚度显著减小（
P
＜0.05）。
结论
2
桃红四物汤加味颗粒可通过抑制DKD模型大鼠足细胞EMT，减轻肾组织病理损伤及足细胞损伤，从而保护肾功能、延缓肾脏纤维化进展。
Abstract
OBJECTIVE
2
To investigate the effects of Taohong siwu decoction modified granules on podocyte epithelial-mesenchymal-transition （EMT） and renal fibrosis in diabetic kidney disease （DKD） model rats.
METHODS
2
Eight rats were selected as normal group （ordinary feed）； the remaining rats were given a high-glucose and high-fat diet combined with intraperitoneal injection of streptozotocin （35 mg/kg） to induce the DKD model. Model rats were randomly divided into model group， irbesartan group [positive control， 13.5 mg/（kg·d）
]
and modified Taohong siwu decoction group [6.48 g/（kg·d）
]
， with 8 rats in each group. All groups were given relevant medicine intragastrically， once a day， for 16 consecutive weeks. Twenty-four-hour urinary total protein （24 h UTP） was detected at the end of the 4th， 8th， 12th and 16th week of administration. After the last medication， the body mass， water intake， food intake， urine output， the levels of fasting blood glucose， serum creatinine （Scr） and blood urea nitrogen （BUN） as well as mRNA and protein expressions of P-cadherin， nephrin，
α
-smooth muscle actin （
α
-SMA）， Wilms’ tumor gene 1 （WT1）， transforming growth factor-β
1
（TGF-β
1
） and type Ⅳ collagen （Col-Ⅳ） in renal tissue were determined. The pathological and morphological changes in renal tissue were observed and the thickness of the glomerular basement membrane was determined.
RESULTS
2
Compared with the model group， 24 h UTP of rats wa
s significantly decreased in modified Taohong siwu decoction group since the 8th weekend （
P
＜0.05）； the body weight of rats increased significantly， but the amount of water intake and urine decreased significantly； Scr and BUN level， mRNA expression of
α
-SMA， mRNA and protein expressions of TGF-β
1
and Col-Ⅳ were significantly reduced， while the mRNA expressions of P-cadherin， nephrin and WT1 were increased significantly （
P
＜0.05）； the protein deposition of
α
-SMA was reduced， protein depositions of P-cadherin， nephrin and WT1 were increased； the pathological damage and fibrosis of renal tissue were relieved； the thickness of glomerular basement membrane was decreased significantly （
P
＜0.05）.
CONCLUSIONS
2
Taohong siwu decoction modified granules can inhibit the EMT of podocyte in DKD model rats， and alleviate renal pathological damage and podocyte damage， thus protecting renal function， and delaying the process of renal fibrosis.
关键词
糖尿病肾病桃红四物汤加味颗粒肾脏纤维化足细胞上皮-间充质转化
Keywords
Taohong siwu decoction modified granulesrenal fibrosispodocyteepithelial-mesenchymal-transition
references
International Diabetes Federation. IDF diabetes atlas，10th edition[EB/OL].[2022-10-23]. https：//diabetesatlas.org/data/upload/download/global_factsheet_en.pdfhttps://diabetesatlas.org/data/upload/download/global_factsheet_en.pdf.
LIN E，ERICKSON K F. Payer mix among patients recei-ving dialysis[J]. JAMA，2020，324（9）：900-901.
ZHANG L X，LONG J Y，JIANG W S，et al. Trends in chronic kidney disease in China[J]. N Engl J Med，2016，375（9）：905-906.
余学清，赵明辉. 肾内科学[M]. 3版. 北京：人民卫生出版社，2021：71-75.
YU X Q，ZHAO M H. Nephrology[M]. 3ed. Beijing：People’s Health Publishing House，2021：71-75.
SHANKLAND S J，WANG Y L，SHAW A S，et al. Podocyte aging：why and how getting old matters[J]. J Am Soc Nephrol，2021，32（11）：2697-2713.
吴其晶，杨倩倩. 足细胞衰老与肾小球疾病[J]. 肾脏病与透析肾移植杂志，2023，32（5）：472-476.
WU Q J，YANG Q Q. Advance in glomerular disease and podocyte senescence[J]. Chin J Nephrol Dial Transplant，2023，32（5）：472-476.
陈海云，敖英，朱亚男，等. 足细胞上皮-间充质转分化与肾小球疾病[J]. 临床肾脏病杂志，2020，20（5）：425-430.
CHEN H Y，AO Y，ZHU Y N，et al. Podocyte epithelial-mesenchymal transdifferentiation and glomerular disease[J]. J Clin Nephrol，2020，20（5）：425-430.
YING Q D，WU G Z. Molecular mechanisms involved in podocyte EMT and concomitant diabetic kidney diseases：an update[J]. Ren Fail，2017，39（1）：474-483.
肖遥，黄为钧，赵进喜. 从“癥瘕致病、虚实相因” 探讨早期糖尿病肾病的治疗[J]. 环球中医药，2021，14（12）：2184-2186.
XIAO Y，HUANG W J，ZHAO J X. Discussion on the treatment of early diabetic nephropathy from the perspective of “the cause of illness and the cause of deficiency and excess” [J]. Glob Tradit Chin Med，2021，14（12）：2184-2186.
陈慧楠，林敏. 糖尿病肾病从络病论治研究进展[J]. 中国实验方剂学杂志，2022，28（8）：265-271.
CHEN H N，LIN M. Treatment of diabetic nephropathy from collateral diseases：a review[J]. Chin J Exp Tradit Med Formulae，2022，28（8）：265-271.
陈凯丽，陈占科，陈昺伃，等. 含虫类药处方治疗糖尿病肾病的用药规律[J]. 实用临床医药杂志，2022，26（18）：87-92，97.
CHEN K L，CHEN Z K，CHEN B Y，et al. Medication rules of insect-containing prescriptions in treatment of diabetic nephropathy[J]. J Clin Med Pract，2022，26（18）：87-92，97.
黎娅，范培云，马晓雨，等. 长期稳定的SD大鼠2型糖尿病模型制备方法[J]. 中国实验动物学报，2020，28（3）：364-369.
LI Y，FAN P Y，MA X Y，et al. A long-term and stable method for the preparation of a type 2 diabetes Sprague-Dawley rat model[J]. Acta Lab Animalis Sci Sin，2020，28（3）：364-369.
邹万忠. 肾活检病理学[M]. 5版. 北京：北京大学医学出版社，2021：370-375.
ZOU W Z. Renal biopsy pathology[M]. 5ed. Beijing：Peking University Medical Press，2021：370-375.
王婉懿，王悦芬. 中药干预足细胞上皮间质转分化治疗糖尿病肾病的研究进展[J]. 环球中医药，2022，15（10）：1969-1976.
WANG W Y，WANG Y F. Research progress on podocyte epithelial-mesenchymal transition in diabetic nephropathy and intervention effect of traditional Chinese medicine[J]. Glob Tradit Chin Med，2022，15（10）：1969-1976.
李童，赵媛媛，杨发奋. 足细胞标志蛋白在足细胞病中的研究进展[J]. 右江医学，2022，50（1）：72-75.
LI T，ZHAO Y Y，YANG F F. Research progress of podocyte marker protein in podocyte disease[J]. Chin Youjiang Med J，2022，50（1）：72-75.
胡欣欣，孟晓凡，徐圣洁，等. TGF-β1/Smad信号通路与肾间质纤维化[J]. 生命的化学，2023，43（4）：601-609.
HU X X，MENG X F，XU S J，et al. TGF-β1/Smad signa- ling pathway and renal interstitial fibrosis[J]. Chem Life，2023，43（4）：601-609.
白璐，沈士朋，王倩，等. 通心络胶囊对糖尿病肾病模型大鼠肾纤维化的干预作用[J]. 中国药房，2023，34（13）：1584-1589.
BAI L，SHEN S P，WANG Q，et al. Intervention effect of Tongxinluo capsule on renal fibrosis in diabetic nephropathy rats[J]. China Pharm，2023，34（13）：1584-1589.
0
Views
0
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.